Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Szocinski, J. L.
Right arrow Articles by Murphy, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Szocinski, J. L.
Right arrow Articles by Murphy, W. J.
Related Collections
Right arrow Neoplasia
Right arrow Immunotherapy
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 1 July 2002, Vol. 100, No. 1, pp. 217-223

NEOPLASIA

Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax

Jamie L. Szocinski, Annette R. Khaled, Julie Hixon, Douglas Halverson, Satoshi Funakoshi, William C. Fanslow, Ann Boyd, Dennis D. Taub, Scott K. Durum, Clay B. Siegall, Dan L. Longo, and William J. Murphy

From the Laboratory of Leukocyte Biology, Laboratory of Molecular Immunoregulation, and SAIC-Frederick, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, Maryland; Laboratory of Immunology, National Institute on Aging, Baltimore, Maryland; Immunex Corporation, Seattle, Washington; Biology Department, Hood College, Frederick, Maryland; and Seattle Genetics, Bothell, Washington.

CD40 is present on both normal and neoplastic B-lineage cells. CD40 stimulation of normal B cells has been shown to promote normal growth and differentiation, whereas aggressive histology B lymphomas are growth inhibited. The inhibition of neoplastic B-cell growth is believed to occur via activation-induced cell death in which stimuli that typically promote the growth of normal cells prevent the growth of their neoplastic counterparts. We show here that CD40 stimulation using either a soluble recombinant human CD40 ligand (srhCD40L) or anti-CD40 monoclonal antibody resulted in apoptosis of human Burkitt lymphoma cell lines. Additional studies examining the mechanism of CD40-mediated death revealed an increase in bax messenger RNA with a subsequent increase in Bax protein in the mitochondria of the treated cells. In vitro exposure of the cells to bax antisense oligonucleotides resulted in a significant decline in Bax protein levels and partial protection from CD40-mediated death, indicating that induction of Bax was at least one mechanism underlying this inhibitory effect of CD40 stimulation on lymphomas. When immunodeficient mice bearing Burkitt lymphoma were treated with srhCD40L, significant increases in survival were observed indicating a direct antitumor effect as a result of CD40 stimulation in vivo. Overall, these results demonstrate that CD40 ligation of aggressive histology B-lymphoma cells results in inhibition both in vitro and in vivo and thus may be of potential clinical use in their treatment.

© 2002 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Neurosci.Home page
Y. Zhu, J. Antony, S. Liu, J. A. Martinez, F. Giuliani, D. Zochodne, and C. Power
CD8+ lymphocyte-mediated injury of dorsal root ganglion neurons during lentivirus infection: CD154-dependent cell contact neurotoxicity.
J. Neurosci., March 29, 2006; 26(13): 3396 - 3403.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C.-L. Law, K. A. Gordon, J. Collier, K. Klussman, J. A. McEarchern, C. G. Cerveny, B. J. Mixan, W. P. Lee, Z. Lin, P. Valdez, et al.
Preclinical Antilymphoma Activity of a Humanized Anti-CD40 Monoclonal Antibody, SGN-40
Cancer Res., September 15, 2005; 65(18): 8331 - 8338.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
A. J. Olszewski and M. L. Grossbard
Empowering Targeted Therapy: Lessons from Rituximab
Sci. Signal., July 13, 2004; 2004(241): pe30 - pe30.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. R. Jazirehi and B. Bonavida
Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis
Mol. Cancer Ther., January 1, 2004; 3(1): 71 - 84.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
F. Giuliani, C. G. Goodyer, J. P. Antel, and V. W. Yong
Vulnerability of Human Neurons to T Cell-Mediated Cytotoxicity
J. Immunol., July 1, 2003; 171(1): 368 - 379.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Linderoth, M. Jerkeman, E. Cavallin-Stahl, S. Kvaloy, and E. Torlakovic
Immunohistochemical Expression of CD23 and CD40 May Identify Prognostically Favorable Subgroups of Diffuse Large B-cell Lymphoma: A Nordic Lymphoma Group Study
Clin. Cancer Res., February 1, 2003; 9(2): 722 - 728.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020